Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer (2021)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ccell.2021.10.003
PubMed Identifier: 34678151
Publication URI: http://europepmc.org/abstract/MED/34678151
Type: Journal Article/Review
Parent Publication: Cancer Cell
Issue: 11
ISSN: 1535-6108